Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules

US10745473B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Matthew John EDWARDS · Horsham, GB
• Jean-Michel Rene Rondeau · Rixheim, FR
• Danforth Miller · Redwood City, US
• Daniel Huang · Palo Alto, US
• Hans-Peter Knopf · Schallstadt, DE
• Gino Van Heeke · Gainesville, US
• Rene HEMMIG · Basel, CH
• Kapil Gupta · Concord, US
• Nicole HAUBST · Munich, DE
• Barbara ANDLAUER · Planegg, DE

Key dates

• Filing date: May 8, 2018
• Grant date: Aug 18, 2020
• Expiry date: Jan 13, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.